If you’re looking for a poster child for something this administration is doing that has no apparent support from anyone, I think you’ve got your winner.

U.S. outpatient prescriptions for hydroxychloroquine and ivermectin increased 2- to 10-fold above pre-pandemic rates, respectively, to treat COVID-19, despite strong evidence disproving their ...